Michele Brown

Michele Brown serves as a key procurement professional within the National Cancer Institute (NCI), part of the National Institutes of Health, where she manages complex research and development acquisitions aligned with the agency’s mission to accelerate cancer diagnostics and precision therapeutics. She oversees the solicitation and award of contracts for high-performance laboratory services, genomic analysis platforms, and translational research infrastructure, ensuring alignment with federal acquisition regulations and NCI’s scientific priorities. Her work directly supports the development of next-generation oncology tools by facilitating access to advanced scientific capabilities through competitive and compliant contracting mechanisms. Brown maintains a primary working relationship with Roche Diagnostics Corporation, a leading provider of molecular diagnostics and life science research solutions. Her procurement pattern reflects a strategic reliance on established, high-capacity industry partners with proven expertise in oncology assay development, next-generation sequencing systems, and bioinformatics platforms. These vendor relationships are characterized by long-term, performance-driven engagements that prioritize technical rigor, regulatory compliance, and scalable innovation capacity. Her contracting activity shows no use of socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a procurement strategy focused on technical excellence and mission-critical capability over socioeconomic preferences, prioritizing the most qualified vendors regardless of business size or certification status. Brown’s procurement portfolio is exclusively concentrated under NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—emphasizing contract types such as cost-reimbursement, time-and-materials, and basic ordering agreements for laboratory services, clinical trial support, and biomarker discovery platforms. Her domain expertise lies in procuring advanced life sciences technologies that enable genomic profiling, targeted therapy development, and data-driven cancer research initiatives.